Investor Presentaiton
Consolidated Financial Performance (reported)
zydus
Dedicated To Life
Q4
04
YoY
03
000
Rs. mn
FY22
FY21
Gr.
FY22
Total Income from Ops.
Gross Contribution (GC)
FY21
38,638 36,703
23,680 24,339
gr.
FY22
gr.
Gross Margin %
61.3% 66.3%
5.3% 36,398
-2.7% 23,064
63.4%
Employee benefits expenses
*
R&D expenses
Other operating expenses
EBITDA
8,405 8,267
7,177 8,495 -15.5%
5,401 5,311
2,697 2,266 19.0%
1.7%
1.7% 5,287
2.2%
2,553
5.6%
7,708
9.0%
6.2% 1,52,652 1,44,035 6.0%
2.7% 97,200 96,014 1.2%
63.7% 66.7%
21,974 20,954 4.9%
10,406 11,196 -7.1%
31,413 29,993 4.7%
Comments for 04 FY22:
GC
impacted by
inventory provision of Rs. 1.4 bn.
one-time
7,516
-4.5%
33,407 33,870 -1.4%
EBITDA Margin %
18.6% 23.1%
20.6%
21.9% 23.5%
Other Income
Finance cost
791
385
-304 360.2%
607
30.3%
2,247
456 392.8%
•
Adj. for one-time
Depreciation and amortization
Profit before exceptional items
5,729
232 65.9%
1,854 1,753 5.8%
6,206 -7.7% 6,042
311
23.8%
1,270
1,588
-20.0%
1,770
4.7%
7,130
6,696
6.5%
-5.2%
27,254
26,042
4.7%
Profit after exceptional items
5,729
5,475
Tax expenses
1,092 -2,060
4.6% 6,042
153.0% 1,094
-5.2%
28,381
23,991 18.3%
Share of profit from JVs
46
Profit from discontinued operations #
-150
Minority Interest
559
Reported Net Profit
3,974
38 21.1%
-219 31.5%
564 -0.9%
6,790 -41.5%
-0.2%
223 -79.4%
-65 -130.8%
102 448.0%
5,004 -20.6%
5,117
1,936 164.3%
462
22,457
1,310
44,873
474 -2.5%
-680
Opex increased QoQ due to
increased marketing spend (incl.
Wellness) and freight cost.
inventory
provision, Q4 FY22 EBITDA was
Rs. 8,612 mn (22.3% margin).
Adj. Net Profit for Q4 FY22 was
Rs. 5,250 mn, up 12% YoY.
514 154.9%
21,335 110.3%
* Excludes Research related expenses
# Discontinued operations refer to divested India-centric Animal Health Business and discontinuation of Nesher and Hercon business.
13View entire presentation